Physician profile
Abhay Agarwal
NPI 1770672057
$3,670.65
in general payments reported to CMS, 2019-2025
27 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $157 · 2021: $496 · 2022: $373 · 2023: $535 · 2024: $689 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $987.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $518.11 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $405.01 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $330.77 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $253.35 | 2019-2022 | |
| Exact Sciences Corporation | $154.27 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $121.04 | 2023-2025 | Repatha, Repatha, Otezla |
| Dexcom, INC. | $114.85 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.51 | 2025 | Jardiance |
| Grifols USA, LLC | $79.62 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $77.28 | 2019-2021 | |
| Phadia US INC. | $75.69 | 2019-2024 | Immunocap |
| Pfizer INC. | $70.52 | 2019-2025 | |
| Abbott Laboratories | $62.16 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $57.71 | 2019-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $40.41 | 2023 | Tymlos |
| Photonicare INC | $29.23 | 2025 | Otosight Middle Ear Scope |
| Terumo Medical Corporation | $26.40 | 2023 | Angio-Seal |
| Biohaven Pharmaceutical Holding Company LTD. | $24.75 | 2022 | |
| Boston Scientific Corporation | $23.68 | 2023 | |
| Medtronic, INC. | $22.15 | 2022 | |
| Abiomed | $17.37 | 2025 | |
| Gilead Sciences, INC. | $15.76 | 2020 | |
| Genentech USA, INC. | $15.10 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.81 | 2025 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2025 | Xifaxan |
| Bavarian Nordic A/S | $14.37 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhay Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.